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Abstract
Background: Opioid-related morbidity and mortality is a serious public health issue in the United
States. Prescription Drug Monitoring Program (PDMP) review prior to prescribing opioids has
consistently been recommended as best practices for risk mitigation, however, access/utilization
of this monitoring program remains low.
Methods: This quality improvement (QI) project for improved PDMP utilization employed a prepost survey design in a random sample of Advanced Practice Registered Nurses in Arizona.
Quantitative measures included online surveys with close-ended responses to salient items from
the review of literature and best practices. A follow-up survey was requested of the participants
who provided their email address one month following initial survey/best practice review.
Results: Forty-six APRNs responded to the preliminary survey. Of the initial respondents, 22
completed the post-intervention survey one month after the QI activity. APRNs reported
improved compliance with best practice recommendations including initial PDMP review prior
to prescribing opioid medication for non-cancer, non-terminal pain, reviewing morphine
milligram equivalents (MMEs) of prior prescriptions, < 3 month PDMP review for patients
receiving chronic opioid medication, APRN addressing concerning PDMP review results, and
maintaining an opioid dosage < 50 MMEs.
Conclusions: Targeted educational awareness for APRNs can improve utilization of PDMPs and
support increased adherence to safe, opioid prescribing best practices.
Keywords: Opioid prescribing, prescription drug monitoring programs

MITIGATING PRESCRIPTION OPIOID RISK

7

Mitigating Prescription Opioid Risk: Prescription Drug Monitoring Programs
Introduction
In the next hour, eight Americans will die from an opioid overdose. Of that number, four
will be from prescription opioids (Centers for Disease Control and Prevention [CDC], 2017).
Prescription opioid deaths are preventable. One method of risk mitigation involves utilizing
Prescription Drug Monitoring Programs (PDMPs). PDMPs gather, observe, and analyze
electronically transmitted, patient-specific, controlled substances data submitted by pharmacies
and dispensing practitioners. Reviewing the PDMP has consistently been recommended as best
practice for reducing prescription opioid morbidity and mortality risk (Chou et al., 2014; Dowell,
Haegerich, & Chou, 2016). However, utilization rates remain low. For example, findings reveal
only 22% of Arizona prescribers were registered with the Arizona Controlled Substances
Prescription Monitoring Program (AZCSPMP) (Dodge, 2017). Actual utilization is likely even
lower. Failure to check the PDMP can result in the patient receiving a lethal medication
combination.
Background
The United States (U.S.) accounts for approximately 5% of the world’s population but
consumes 80% of the global opioid supply (International Narcotics Control Board, 2009).
Opioid prescriptions in the U.S. have increased since 1999 with a concurrent increase in opiaterelated deaths (CDC, 2011; Hedegaard, Warner, & Miniño, 2017) and are responsible for almost
half of overdose deaths (Rudd, Seth, David, & Scholl, 2016). Annual U.S. overdose deaths now
surpass the number from auto accidents (U.S. Department of Health & Human Services [DHHS],
2015).
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Significant historical events contributed to opioid pain reliever (OPR) popularity.
Pharmaceutical company, Purdue Pharma, released OxyContin to the market in 1995. An
aggressive marketing campaign included financial grants encouraging the use of OPRs in
chronic, non-cancer pain. The American Pain Society began the “pain is the fifth vital sign”
campaign which the Joint Commission also adopted. Pain was given the same clinical
significance as objective findings such as temperature, pulse, respiration rate, and blood pressure.
Despite lack of evidence for long-term efficacy, OPR prescriptions continue to rise (Hedegaard,
et al., 2017; Kolodny et al., 2015).
In response to the surge in opioid-related morbidity and mortality, the CDC (2017) issued
a state-wide “call to action.” Accordingly, on June 5th, 2017, Arizona Governor Douglas Ducey
declared a public health emergency (State of Arizona, 2016) and created a task force to address
this epidemic (Arizona Department of Health Services [ADHS], 2017a). The ensuing Opioid
Overdose Epidemic Response Report provided recommendations consistent with best practice
guidelines (ADHS, 2017b), including a mandate requiring that prior to prescribing a Schedule II,
III or IV opioid analgesic or benzodiazepine, a provider must acquire a PDMP patient utilization
report for the preceding 12 months (Amending Sections 36-2606 and 36-2608, 2016).
The CDC has provided twelve recommendations for long-term prescription opioid use in
adults ages 18 and older with chronic, non-cancer, non-terminal pain. These include three main
categories. One category is targeted at assessing risk and addressing opioid use harms (Dowell,
et al., 2016). Risk mitigation strategies correspond with the Institute of Medicine [IOM] (2001)
dimensions of quality, specifically safe and effective care. Improved safety is reflected by
decreased morbidity and mortality from an adverse event or harm. Several studies have
supported introduction of a state PDMP and reductions in strength and/or quantity of opioid
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prescriptions (Bao et al., 2016; Deyo et al., 2018; Wen, Schackman, Aden, & Bao, 2017;
Yarbrough, 2017) as well as a reduction in opioid-related deaths (Patrick, Fry, Jones, & Buntin,
2016) and opioid abuse (Reifler et al., 2012). National and local publicity highlighting the
opioid crisis is a “hot button” topic reinforcing best practice implementation. While providers
are invested in safe care, barriers to best practice implementation exist. Provider practice varies,
with some providers monitoring the PDMP while others do not.
Problem Statement
The risk of overdose/death among Arizona adults 18 years of age and older prescribed
long-term opioids for non-cancer, non-terminal pain is indicated by morbidity and mortality
statistics and results from deficits in risk identification including prescriber utilization of the state
PDMP. A Quality Improvement (QI) project which promotes improvement of AZCSPMP
utilization is suggested.
Organizational “Gap” Analysis of Project Site
The Agency for Health Care Research and Quality (AHRQ) supports quality and safety
as it relates to prescribing long-term opioids for chronic pain (Chou et al., 2014). The gap
relates to the Arizona state mandate requiring providers check the AZCSPMP prior to
prescribing controlled substances and at minimum specific intervals thereafter. Despite
legislative mandate, prescriber registration and utilization are low.
Review of the Literature
A database search of PubMed and The Cumulative Index to Nursing and Allied Health
Literature (CINAHL) was performed for articles dated January 1, 2013 to present. Medical
Subject Headings (MeSH) terms searched in both databases were prescription drug monitoring
programs AND utilization and prescription drug monitoring programs AND barriers. One
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hundred fifty-one articles were retrieved from the search, including 91 articles from PubMed and
60 from CINAHL. The database search on PDMPs and utilization yielded 66 articles from
PubMed and 44 from CINAHL. PDMPs and barriers generated 25 and 16 articles from PubMed
and CINAHL, respectively. Publications were reviewed for inclusion. Of the articles on PDMPs
and utilization, 50 were excluded from the PubMed results and 36 from CINAHL. Twelve
articles were excluded from the PubMed results and nine from the CINAHL search on PDMPS
and barriers. Inclusion criteria for the review was full-text, peer-reviewed, English language
articles. Excluded articles were four editorials, four best practices/guidelines, 11 focusing on
pharmacists, 49 specific to patient level date, nine relating to PDMP policy, and five educational
articles. Additional excluded articles consisted of one case study, 15 irrelevant articles, two poor
quality studies, and 16 policy reviews. Also, one article written in Spanish and three articles
which were not peer-reviewed were omitted. Poor quality studies lacked adequate sample size,
response rate, and/or were poorly designed. Irrelevant articles either focused on an unrelated
topic or opioid dispensing. Lastly, 27 duplicate articles were excluded. Review of article
reference lists identified two additional articles for inclusion. Six articles remained for review
and synthesis.
The six selected studies on PDMPs and opioid prescribing practices included one
retrospective cohort study, one systematic review of case-control studies, one cross-sectional
random sample survey, two cross-sectional non-randomized surveys, and one qualitative
interview study. The strength of recommendations and quality of the evidence was evaluated
utilizing The Johns Hopkins Nursing Evidence-based Practice Rating Scale. Based upon
scientific study design, strength of evidence is rated from a high of Level I to a low of Level V.
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The quality of evidence represents the level of expertise evident and is rated high, medium, or
low (Newhouse, Dearholt, Poe, Pugh, & White, 2005).
PDMP Utilization
PDMP utilization varies. A frequent theme found prescribers rely heavily on their
subjective impression of a patient when determining if PDMP review is indicated (Leichtling et
al., 2016; Lin et al., 2018; Smith et al., 2015; Young et al., 2017). Leichtling et al., (2017)
evaluated a purposive sample of PDMP utilization. Short-term prescribers i.e., those working in
acute care facilities, reported inconsistent use of the PDMP. Long-term prescribers, were more
likely to check the PDMP for new patients and at spaced intervals for long-term patients.
Strength of evidence: Level III, Quality Level medium (Newhouse, et al., 2005). However,
physicians working in a managed care organization were less likely to utilize PDMP (Lin et al.,
2018). Strength of evidence: Level III, Quality Level medium (Newhouse et al., 2005).
Pomerleau et al. (2016) found a mere 8% (n = 18) of surveyed emergency department (ED)
prescribers check the PDMP with each patient. Strength of evidence: Level III, Quality Level
medium (Newhouse et al., 2005).
PDMP use was evaluated in a survey of physicians practicing in primary care, pain
medicine and emergency medicine (Lin et al., 2017). Participants utilizing the PDMP reported it
was very easy (33%, n = 82) or somewhat easy (47%, n = 114) to use. Strength of evidence:
Level II, Quality Level medium (Newhouse et al., 2005). Other studies suggest significant
barriers.
PDMP Barriers
Provider perception and satisfaction with the PDMP can affect utilization. PDMP
utilization and perception was evaluated by Young, Tyndall, and Cottler (2017). Survey results
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suggested barriers including difficulties in initial access, frequent password renewal, and timing
out requiring re-entry of username/password. Strength of evidence: Level III, Quality Level low
(Newhouse et al., 2005). Lin et al. (2017) also found 20% of respondents reported access issues.
Similarly, Smith et al. (2015) found barriers including lack of awareness as well as access and
time constraints. Strength of evidence: Level III, Quality Level medium (Newhouse et al.,
2005). A survey of 515 emergency department (ED) providers revealed only 59% of
respondents was registered with their PDMP. Fifty-three percent reported consulting the PDMP
at least once a shift. Sixty-three percent reported being satisfied (47%) or very satisfied (16%)
with the state PDMP (Pomerleau et al., 2016).
Several limitations are noted. Self-report and retrospective information can impact
reliability and validity of findings. The lack of randomized clinical trials reduces data quality.
Additionally, use of local/state-specific and non-randomized samples limit generalizability of
data (Gravetter & Forzano, 2016).
Utilization of the PDMP varies; lack of sanctions for non-compliance with state PDMP
requirements may play a role in the findings. Subjective impression as criteria for PDMP
utilization was supported by four studies (Leichtling et al., 2016; Lin et al., 2018; Smith et al.,
2015; Young et al., 2017). While some individuals with substance use disorders have some
similar physical characteristics, not all individuals look the same. Objective data is necessary to
reduce the risk of targeting certain individuals and missing serious substance abuse in others.
Lack of standardized state PDMP guidelines and enforcement of state mandates may limit data
utility. Despite governmental mandates, there is no standardized use of the PDMP. Information
on ease of access is conflicting. Some prescribers report logistical interference. This could
reflect user skill, time constraints, or individual provider decision.
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Provider compliance with risk mitigation strategies supports best practices and IOM
(2001) quality domains. A QI project to support/improve PDMP utilization and PDMP access
was indicated. The goal was decreased morbidity and mortality by reducing high-risk opioid
prescribing for patients with non-terminal, non-cancer pain.
Evidence Based Practice: Verification of Chosen Option
Reviewing the PDMP is recommended as best practice when prescribing long-term
opioids (Chou et al., 2014; Dowell, et al., 2016). Risk assessment and mitigation strategies,
including reviewing the PDMP, are recommended to reduce the risk of unintentional
overdose/death. Providers may alter their treatment plan after reviewing information from the
PDMP by reducing the quantity, strength, or duration of opioids prescribed.
Theoretical Framework/Evidence Based Practice Model
Fishbein and Ajzen’s (2010) Theory of Reasoned Action and Planned Behavior (most
recently referred to as The Reasoned Action Approach) (Appendix A) is a theoretical framework
developed to explore ways of predicting behaviors and outcomes. They propose attitudes and
perceived “norms” have an effect on behavior, that behavior is a function of behavioral
intentions and perceived behavioral control (Fishbein & Ajzen, 2010). For example, emergent
governmental interventions and recent policy changes may be associated with an attitude change
about opioid prescribing “norms.” Clinicians' attitude toward the mandate and utility of the
program affect use. If prescribers perceive checking the PDMP as the new “norm,” there is
increased probability providers will change their perspective on prescribing long-term opioids.
The outcome measure was the behavior, in this case, PDMP review.
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Goals, Objectives and Expected Outcomes
Goals for the Capstone project included identifying facilitators and barriers of PDMP
utilization and increasing APRN knowledge about PDMP utilization when prescribing long-term
opioids for chronic pain.
The objectives for this DNP project were to evaluate facilitating factors and barriers to
utilization of the AZCSPMP and provide an online video review for PDMP best practices when
prescribing opioid medication for non-cancer, non-terminal pain.
The main outcome was improved utilization of the Arizona PDMP. Utilization was
defined as initial PDMP review prior to prescribing opioid medication for non-cancer, nonterminal pain, reviewing morphine milligram equivalents (MMEs) of prior prescriptions, <3month PDMP review for patients receiving chronic opioid medication, APRN addressing
concerning PDMP review results, and maintaining an opioid dosage < 50 MMEs. It was
anticipated that a QI video reviewing best practices would result in improved utilization of the
AZCSPMP.
The target for the outcome indicators was 30 percent compliance for all at baseline and
60 percent at one month post initial survey/QI activity. The target benchmark, an external
benchmark, was set relative to the current state PDMP utilization rates for all prescribing
providers prior to the surveys and QI presentation.
Methods
The proposed QI project utilized a random sample of Arizona advanced practice
registered nurses (APRNs). The sampling frame was entered into the Excel sheet.
Randomization occurred using the “= RANDBETWEEN()” function. A pre-/post-survey design
was utilized. Quantitative measures included online surveys with close-ended responses to
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salient items from the review of literature and best practices. The QI intervention, a risk
mitigation video reviewing evidence-based practices for prescribing opioids, as well as
requirements of the Arizona mandate, was presented to APRNs immediately following
participants’ completion of the preliminary survey. A follow-up survey was requested of the
participants who provided their email address one month after initial survey/best practice review.
Project Site
An Arizona behavioral health organization provided clinical support for the Capstone
QI project. The business has a 31-year history of providing comprehensive, medically-integrated
behavioral health programs. They provide substance abuse treatment including detoxification,
residential, and medication-assisted treatment. Additionally, the organization provides integrated
care treatment for co-morbid medical conditions including prevention, education, and treatment
services using nationally recognized treatment models. Services are provided at multiple sites
throughout Arizona.
The DNP student, as project director, provided a summary of findings to administrative
members at project competition. This will assist administration with future QI initiatives for
provider prescribing. The findings will be particularly salient for ongoing QI efforts on safe
prescribing practices including treatment of anxiety and substance use disorders as well as
integrated health care.
The project took place via online survey. Required resources included APRN addresses,
mailing materials, online survey site, online QI activity, and follow-up capacity. The main
barrier was the means available for contacting APRNs licensed to practice in Arizona. By
policy, the Arizona Board of Nursing will only release mailing addresses of licensed nurses, not
email addresses (Arizona State Board of Nursing, 2018). The project director requested the
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mailing list. Email communication with Kathy Malloch, PhD, MBA, RN, FAAN, Associate
Director/Education and Evidence Based Regulation at Arizona State Board of Nursing confirmed
approved use of the requested APRN list for the QI project (Appendix B). The acquired list
included the names of 8817 APRNs with active Arizona licenses. The cost of mailing to all
Arizona APRNs was cost prohibitive, therefore a random sample of 1700 was selected. Other
potential resources for email addresses included the Arizona Board of Pharmacy who manages
the AZCSPMP and the American Academy of Nurse Practitioners. The DNP student sent email
communications to these two potential sources inquiring on the availability of an email list of
APRNs without success.
Population
Inclusion criteria were APRNs with active Drug Enforcement Administration (DEA)
certificates and prescribing privileges within the state of Arizona completing pre- and postsurvey and QI activity. Additional inclusion criteria consisted of APRNs who prescribe opioids
for non-cancer, non-terminal pain in the state of Arizona from August 2018 through February
2019. Individuals falling outside of the above noted criteria were excluded.
The DNP student, as project director, was responsible for all phases of project
development, implementation, data collection, data analysis, and evaluation. The implementation
plan/procedures contained the following steps: proposal write-up and approval, obtaining
mailing list of APRNs practicing in Arizona, creating and ordering postcards, mailing
postcards/email requesting participation. A copy of the postcard content is included in Appendix
C. The next steps were developing an online survey by adapting a previously developed PDMP
survey, posting the survey on Survey Monkey, creating and including a link to the QI activity at
the end of the first survey, followed by requesting participants complete a follow-up survey one
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month after QI activity. The last steps included collecting, cleaning, and analyzing the data and
final write-up.
The goal sample size was determined utilizing an online calculator at SurveyMonkey.
The total population size was 8819. With a standard confidence interval of .80 and a margin of
error of 0.05, a sample of at least 161 was required. The anticipated response rate for an external
mail survey is 10% (Gravetter & Forzano, 2016). To obtain the minimum sample size, at least
1610 invitations needed to be mailed; however, 1700 was the number of invitations mailed.
Measurement Instruments
The outcome variable was PDMP utilization via best practice behaviors and requirements
of the Arizona mandate. Coinciding with the theoretical framework, it was posited that attitude,
outcome expectancies, perceived norms, perceived barriers/control factors, and behavior
intention would influence PDMP utilization. Proposed mediating factors were attitude of PDMP
usefulness, beliefs concerning prescription drug abuse, beliefs regarding peers’ utilization of the
PDMP, perceived social and professional norms, perceived ethical obligation to use the
AZCSPMP, and perceived confidence with or barriers to use of the PDMP. Demographic and
practice data were obtained from the survey. A letter requesting permission to use the 23-item
survey created by Pugliese, Wintemute, and Henry (2018) was mailed to the lead author
(Appendix D). Email communication with the lead study author granting permission was
received and is included in Appendix E. The DNP student created adapted versions of the
survey which included items on risk mitigation strategies/best practices and additional items
reflecting normative behaviors of best practices/risk mitigation. The adapted pre-and postintervention surveys are presented in Appendices F and G. The project included a 35-question
pre-intervention survey, a best practice review video, and a 27-question post-survey.
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Data Collection Procedures
Data collection for the project entailed several steps. A preliminary survey was made
available on SurveyMonkey. Presentation of PDMP utilization best practices to APRNs
occurred as a web link at the end of the first survey. The post-survey was administered to
participants one month after the initial survey/online QI video presentation by the DNP project
director. A follow-up email address was requested in the initial survey to allow for follow-up
communication. Data cleaning and analysis followed.
Ethical Considerations/Protection of Human Subjects
The University of Massachusetts, Amherst (UMASS) IRB approval was obtained prior to
initiating the DNP project and was completed in accordance with UMASS Amherst guidelines
(Moran, Burson, & Conrad, 2014). The official IRB Determination Form was submitted after
the proposal was approved. Care, in accordance with best practices was expected to improve,
therefore risk was minimized, and benefit was anticipated. In order to protect the confidentiality
of human subjects in the QI project, research and IRB review procedure complied with 45 C.F.R.
§ 46 (Protection of Human Subjects, 2009). Safeguards were utilized to assure favorable riskbenefit ratio, respect for participants, informed consent, and independent review. The proposal
involved pre-/post-survey with a QI activity for APRNs. No patient data was collected.
Respect for participants included protecting individually identifiable data elements,
following recommended procedures for data storage and linking for information retrieval. The
DNP project director had sole access to this information which was in a double-locked location.
Protected health information (PHI) was not utilized for any part of the project.
Participant information for this project included: name, city/town, and state which was
only utilized for the initial mailing. Race/ethnicity, clinical specialty, and email address were the
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only participant information collected for the preliminary and post-intervention surveys. This
method assured participants’ anonymity was maintained. Upon project completion, data was
destroyed according to the institutional requirements (Moran, et al., 2014). The Arizona Board
of Nursing and the clinical site expressed support for the QI project and did not require IRB
approval.
Results
Forty-six APRNs (n = 46) responded to the preliminary survey containing quantitative
questions. The pre-intervention survey included two preliminary inclusion questions on
possession of Arizona prescriptive privileges and Federal DEA certificate. One survey was
excluded for lack of a DEA certificate, as that individual could not prescribe Schedule II opioids.
Of the remaining 45 respondents, 22 completed the post-intervention survey. Paired data was
available on 8 participants. The timeline for the project spanned from September 2018-April
2019.
Data Analysis
Analyses were performed on aggregate, quantitative data. An Excel sheet of survey
responses was retained, compiled, and analyzed. Data was scored using IBM’s Statistical
Package for the Social Sciences (SPSS Statistics for Windows, Version 22.0). Data analysis was
accomplished with basic descriptive statistics (frequencies and means/medians) for the
structured-response items as well as demographic data. Relationships between survey items
were analyzed with the nonparametric Spearman’s rank-order correlation. This methodology
was utilized due to the dependent variable being measured on an ordinal level as well as being
highly skewed (Polit, 2010).
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Independent variables included demographic data as well as questions reflecting concepts
from Fishbein and Ajzen’s (2010) Theory of Reasoned Action and Planned Behavior.
Theoretical framework concepts included categories of normative beliefs, attitude, outcome
expectancies, and behavior intention.
Dependent variables were operationalized utilizing five questions specific to opioid
prescribing best practices. Responses were at the ordinal level of measurement on five and sixpoint Likert scales. Responses to the five questions reflecting best practices were transformed to
dichotomous responses. These five variables were recoded to dummy variables for data analysis
with values of 0 (no) and 1 (yes). Only one potential response from each question was coded
affirmatively, reflecting responses every day and always. Results of self-reported best practice
behaviors are presented in Table 1.
Table 1
Self-reported Best Practice Behaviors
Behavior

Preliminary Survey (n = 45)
% (n)

Post-intervention Survey (n = 22)
% (n)

Check initial 12-month PDMP
report prior to prescribing
opioids.

11.1% (5)

31.8% (7)

Review morphine milligram
equivalents (MMEs) or prior
prescriptions.

11.1% (5)

36.4% (8)

Check the CSPMP > every 3
months for patients receiving
opioids.

51.1% (23)

59.1% (13)

Document concerning PDMP
results.

57.8% (26)

63.6% (14)

Maintain an opioid dosage < 50
MMEs per day.

37.8% (17)

50.0% (11)
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Findings suggest increased adherence to best practices across all five recommendations
after online video review. APRNs reported 57.8% compliance with addressing concerning
PDMP review results in the preliminary survey. This increased to 63.6% post-best practice
review, exceeding the 60% target set, and resulted in the objective for that indicator being met.
Targets for the four other indicators were not met. In the preliminary survey, 11.1% reported
initial PDMP review prior to prescribing opioid medication for non-cancer, non-terminal pain
while 31.8% of the post-intervention group reported completing the review. Reviewing MMEs
of prior prescriptions was reported in 11.1% and 36.4% pre- and post-intervention, respectively.
Pre-intervention, 51.1% reported <3-month PDMP review for patients receiving opioids, while
59.1% reported post-intervention adherence. Lastly, maintaining an opioid dosage < 50 MMEs
increased to 50.0% post-implementation from 37.8% reported at baseline.
Demographic information presented in Table 2 was obtained for the preliminary survey
sample (n = 45). The sample was 88.9% female and 11.1% male. Race/ethnicity of participants
included White (91.1%), Black (4.4%), and Asian (4.4%) with 4.4% Hispanic/Latino. Practice
area responses were recoded from the original survey responses to family practice, specialty
clinic, women’s health/midwifery/OBGYN, behavioral health/psychiatry, and urgent/emergency
care/trauma. Recoding was completed based upon the large number of responses listed in the
“other” category.
Skewness indices revealed results of demographic data reflecting gender, race/ethnicity,
Hispanic ancestry, and length of time as an APRN was highly skewed. Survey results on length
of time as an APRN revealed most study participants had less than five years of experience. This
violated the assumptions of a normal distribution and influenced data analysis methods (Polit,
2010).
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Table 2
Demographic and Clinical Characteristics of the Sample Retained for Analysis.
Characteristic
Gender % (n)
Male
Female
Age % (n)
25 to 34
35 to 44
45 to 54
55 to 64
65 to 74
Mean years in practice (n)
Length of time utilizing CSPMP % (n)
Less than 3 months
3-6 months
6-12 months
More than 1 year
Race/ethnicity % (n)
White
Black
American/Alaskan Native
Asian
Native Hawaiian/Pacific Islander
Other
Hispanic or Latino % (n)
Yes
No
Specialty % (n)
Family practice
Specialty clinic
Women’s health/ Midwifery/OBGYN
Behavioral health/psychiatry
Urgent/emergency care/trauma

Pre-best practice review (n=45)

11.1% (5)
88.9% (40)
13.3% (6)
35.6% (16)
26.7% (12)
22.2% (10)
2.2% (1)
8.2 years
2.2% (1)
11.1% (5)
11.1% (5)
75.6% (34)
91.1% (41)
4.4% (2)
0.0% (0)
4.4% (2)
0.0% (0)
0.0% (0)
4.4% (2)
95.6% (43)
28.9% (13)
28.9% (13)
11.1% (5)
11.1% (5)
20.0% (9)

Normative beliefs were analyzed by questions on professional and moral obligation with
responses on a five-point Likert scale and were operationalized by asking what percentage of
peers the respondent felt should and actually did check the CSPMP at least weekly (Table 3).
In the preliminary survey, 18.2% (n = 8) believed 91-100% of their colleagues utilized
AZCSPMP weekly, while 71.1% (n = 32) thought 91-100% of their colleagues should utilize the
AZCSPMP weekly. Interestingly, in the post-survey, the number of APRNs who believed 91100% of their colleagues used the PMP weekly dropped to 4.5% (n = 1), while there was an
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increase in the number (72.7%, n = 16) who believed 91-100% ought to use the PMP at least
weekly.
Table 3
Quantitative Survey Data by Theoretical Framework Concept of Normative Beliefs
Question

Response

Preliminary (n = 45)
% (n)

Post-Intervention (n = 22)
% (n)

What percentage of your colleagues do
you think uses the CSPMP at least
weekly?

None
1-10%
11-20%
21-30%
31-40%
41-50%
51-60%
61-70%
71-80%
81-90%
91-100%

6.8% (3)
9.1% (4)
0.0% (0)
4.5% (2)
2.3% (1)
13.6% (6)
18.2% (8)
11.4% (5)
9.1% (4)
6.8% (3)
18.2% (8)

0.0% (0)
9.1% (2)
4.5% (1)
9.1% (2)
4.5% (1)
9.1% (2)
9.1% (2)
4.5% (1)
27.3% (6)
18.2% (4)
4.5% (1)

What percentage of your colleagues do
you feel ought to be using the CSPMP at
least weekly?

None
1-10%
11-20%
21-30%
31-40%
41-50%
51-60%
61-70%
71-80%
81-90%
91-100%

0.0% (0)
6.7% (3)
2.2% (1)
0.0% (0)
0.0% (0)
8.9% (4)
2.2% (1)
2.2% (1)
2.2% (1)
4.4% (2)
71.1% (32)

0.0% (0)
4.5% (1)
0.0% (0)
4.5% (1)
0.0% (0)
0.0% (0)
9.1% (2)
0.0% (0)
0.0% (0)
9.1% (2)
72.7% (16)

I have a professional responsibility to
check the CSPMP when prescribing/
dispensing controlled substances.

Strongly disagree
Disagree
Neither disagree or agree
Agree
Strongly agree

0.0% (0)
0.0% (0)
2.2% (1)
20.0% (9)
77.8% (35)

0.0% (0)
0.0% (0)
0.0% (0)
22.7% (5)
77.3% (17)

Checking the CSPMP when prescribing/
dispensing controlled substances is the
right thing to do.

Strongly disagree
Disagree
Neither disagree or agree
Agree
Strongly agree

0.0% (0)
0.0% (0)
2.2% (1)
17.8% (8)
80.0% (36)

0.0% (0)
0.0% (0)
4.5% (1)
13.6% (3)
81.8% (18)

Using the CSPMP when prescribing/
dispensing controlled substances is
considered standard of care.

Strongly disagree
Disagree
Neither disagree or agree
Agree
Strongly agree

0.0% (0)
6.7% (3)
2.2% (1)
24.4% (11)
66.7% (3)

0.0% (0)
0.0% (0)
9.1% (2)
18.2% (4)
72.7% (16)

Prescribing/dispensing controlled
substances without checking the CSPMP
would be morally wrong.

Strongly disagree
Disagree
Neither disagree or agree
Agree
Strongly agree

2.2% (1)
24.4% (11)
35.6% (16)
22.2% (10)
15.6% (7)

0.0% (0)
4.5% (1)
45.5% (10)
22.7% (5)
27.3% (6)

Checking the CSPMP when prescribing/
dispensing controlled substances is not a
necessary part of my job.

Strongly disagree
Disagree
Neither disagree or agree
Agree
Strongly agree

53.3% (24)
35.6% (16)
6.7% (3)
2.2% (1)
2.2% (1)

50.0% (11)
45.5% (10)
0.0% (0)
4.5% (1)
0.0% (0)
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Regarding professional obligation, after the best practice review, an increased percentage
of providers (72.7%, n =16 versus 66.7%, n =30) reported using the CSPMP when prescribing/
dispensing controlled substances is considered standard of care.
Moral obligation also appeared to improve post-intervention with 50.0% (n = 11) versus
37.8% (n = 17) reporting they agreed or strongly agreed prescribing/dispensing controlled
substances without checking the CSPMP would be morally wrong.
Prescriber attitude regarding APRN concern of substance abuse statewide as well as
within their respective practice community was evaluated utilizing a three-point Likert scale and
is presented in Table 4. Providers reported increased concern about substance abuse statewide
(n = 29, 64.4%, ) versus in their practice community ( n = 27, 60.0%) in the preliminary survey.
However, in the post-intervention survey concern was equal for the state and local community
(59.1%, n = 13).
Table 4
Quantitative Survey Data by Theoretical Framework Concept of Attitude
Question

Response

Preliminary (n = 45)
% (n)

Post-Intervention (n = 22)
% (n)

How concerned are you
about prescription drug
misuse and abuse among
patients in Arizona?

Not at all
A moderate amount
A great deal

2.2% (1)
33.3% (15)
64.4% (29)

0.0% (0)
40.9% (9)
59.1% (13)

How concerned are you
about prescription drug
misuse and abuse among
patients in the community
where you practice?

Not at all
A moderate amount
A great deal

4.4% (2)
35.6% (16)
60.0% (27)

4.5% (1)
36.4% (8)
59.1% (13)

Outcome expectancies were garnered from survey questions on perceived PDMP utility
(four-point Likert scale) and perceived PDMP barriers/control factors (five-point Likert scale).
Provider perception of PDMP utility regarding building trust as well identifying patients who
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obtain/fill multiple prescriptions and misuse controlled prescription medication were noteworthy.
Understandably, 50.0% or fewer of providers reported the PDMP was very helpful for building
trust both pre- and post-intervention. Alternatively, most providers reported great utility in
identifying patients who fill multiple controlled substance prescriptions and/or misuse
prescription medication (Table 5).
Table 5
Quantitative Survey Data by Theoretical Framework Concept of Outcome Expectancies: Utility
Question

Response

Preliminary(n = 45)
% (n)

Post-Intervention(n = 22)
% (n)

How useful to you is the Arizona
Controlled Substances Prescription
Monitoring Program (CSPMP) for
helping manage patients with pain?

Not at all useful
Not so useful
Somewhat useful
Very useful

0.0% (0)
4.4% (2)
15.6% (7)
80.0% (36)

0.0% (0)
4.5% (1)
13.6% (3)
81.8% (18)

How useful to you is the CSPMP for
helping build trust with patients?

Not at all useful
Not so useful
Somewhat useful
Very useful

0.0% (0)
13.3% (6)
37.8% (17)
48.9% (22)

0.0% (0)
9.1% (2)
40.9% (9)
50.0% (11)

How useful to you is the CSPMP for
informing decisions to
prescribe/dispense controlled
substances?

Not at all useful
Not so useful
Somewhat useful
Very useful

2.2% (1)
2.2% (1)
17.8% (8)
77.8% (35)

0.0% (0)
0.0% (0)
22.7% (5)
77.3% (17)

How useful to you is the CSPMP for
identifying patients filling
prescriptions from multiple doctors
and/or pharmacies?

Not at all useful
Not so useful
Somewhat useful
Very useful

0.0% (0)
0.0% (0)
6.7% (3)
93.3% (42)

0.0% (0)
0.0% (0)
13.6% (3)
86.4% (19)

How useful to you is the CSPMP for
identifying patients who misuse or
abuse controlled prescription drugs?

Not at all useful
Not so useful
Somewhat useful
Very useful

0.0% (0)
2.2% (1)
26.7% (12)
71.1% (32)

0.0% (0)
0.0% (0)
22.7% (5)
77.3% (17)

Barriers and control factors representing additional theoretical framework concepts of
outcome expectancies are presented in Table 6. Factors specific to perceived barriers and control
included reviewing perceived PDMP utility, relevance, access, and ease of use. After best
practice review, 77.3% (n = 17) strongly agreed the AZCSPMP is helpful and 44.5% (n = 10)

MITIGATING PRESCRIPTION OPIOID RISK

26

reported it was easy to use in contrast to pre-intervention of 66.7% (n = 30) and 42.2% (n = 19),
respectively.
Table 6
Quantitative Survey Data by Theoretical Framework Concept of Outcome Expectances:
Barriers/Control Factors
Question

Response

Preliminary(n = 45)
% (n)

Post-Intervention (n = 22)
% (n)

The CSPMP is helpful.

Strongly disagree
Disagree
Neither disagree or agree
Agree
Strongly agree

2.2% (1)
0.0% (0)
2.2% (1)
28.9% (13)
66.7% (30)

0.0% (0)
0.0% (0)
4.5% (1)
18.2% (4)
77.3% (17)

The CSPMP is not relevant to
my practice.

Strongly disagree
Disagree
Neither disagree or agree
Agree
Strongly agree

57.8% (26)
24.4% (11)
6.7% (3)
8.9% (4)
2.2% (1)

50.0% (11)
40.9% (9)
0.0% (0)
0.0% (0)
9.1% (2)

The CSPMP is easy to use.

Strongly disagree
Disagree
Neither disagree or agree
Agree
Strongly agree

0.0% (0)
6.7% (3)
11.1% (5)
40.0% (18)
42.2% (19)

0.0% (0)
4.5% (1)
4.5% (1)
45.5% (10)
45.5% (10)

I don’t know how to use the
CSPMP.

Strongly disagree
Disagree
Neither disagree or agree
Agree
Strongly agree

62.2% (28)
28.9% (13)
4.4% (2)
4.4% (2)
0.0% (0)

68.2% (15)
27.3% (6)
0.0% (0)
4.5% (1)
0.0% (0)

I have limited or no access to
the CSPMP while I practice.

Strongly disagree
Disagree
Neither disagree or agree
Agree
Strongly agree

62.2% (28)
28.9% (13)
6.7% (3)
2.2% (1)
0.0% (0)

63.6% (14)
27.3% (6)
4.5% (1)
4.5% (1)
0.0% (0)

The CSPMP is checked by
someone else in the office.

Never
Rarely
Sometimes
Usually
Always

44.4% (20)
22.2% (10)
17.8% (8)
11.1% (5)
4.4% (2)

45.5% (10)
13.6% (3)
18.2% (4)
13.6% (3)
9.1% (2)

Behavior intention appeared to increase post-QI intervention. APRNs reporting being
likely or extremely likely to utilize the CSPMP in the next 3 months improved from 91.2% in the
preliminary survey to 95.5% post-intervention (Table 7).
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Table 7
Quantitative Survey Data by Theoretical Framework Concept of Behavior Intention
Question

Response

How likely are you to use
the CSPMP at least once in
the next three months?

Extremely unlikely
Unlikely
Likely
Extremely likely

Preliminary(n = 45)
% (n)

Post-Intervention(n = 22)
% (n)

6.7% (3)
2.2% (1)
15.6% (7)
75.6% (34)

0.0% (0)
4.5% (1)
18.2% (4)
77.3% (17)

Findings did not support a relationship between practice area and best practice adherence
(Table 8). Study outcomes were not consistent with literature review findings of increased
utilization in long-term prescribers. Long-term prescribers were represented by the family
practice category in this sample.
Table 8
Correlation between Practice Area and Best Practice Behaviors

Practice area

Check 12-month
CSPMP prior to
opioid rx.

Review MMEs
prior to opioid rx.

-.075

-.180

-.137

.027

.085

.622

.238

.370

.860

.579

45

45

45

45

45

Document
concerning
PDMP results

Maintain opioid
dosage <50
MMEs per day

Correlation Coefficient
Sig. (2-tailed)
N

Document
concerning
PDMP results

Check CSPMP
every 3 months

Maintain opioid
dosage <50
MMEs per day

Table 9
Correlation between Reported CSPMP Ease of Use and Best Practice Behaviors
Check 12-month
CSPMP prior to
opioid rx.
CSPMP is easy to use

Correlation Coefficient
Sig. (2-tailed)
N

*. Correlation is significant at the 0.05 level (2-tailed).
**. Correlation is significant at the 0.01 level (2-tailed).

Review MMEs
prior to opioid
rx.

Check CSPMP
every 3 months

.376*

.245

.414**

.071

.064

.011

.105

.005

.645

.674

45

45

45

45

45
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Consistent with prior studies, a relationship between reported ease of use and PDMP
utilization was suggested (Table 9). Ease of CSPMP use was positively correlated with checking
the CSPMP prior to prescribing opioids for chronic, non-cancer, non-terminal pain (rs = .376, p <
.05) and checking the CSPMP every three months during opioid treatment (rs = .414, p < .001).
An additional question was added to the post-intervention survey reflecting literature
review findings that suggested prescribers limit checking the PDMP based upon subjective
interpretation. Responses to this question supported prior findings that subjective interpretation
plays a large role in whether they will request an AZCSPMP report. Fourteen out of twenty-two
(63.7%) respondents affirmed utilizing this method of decision making when deciding if
substance misuse was of concern.
Accordingly, no significant relationship was found between best practice behaviors and
checking CSPMP by subjective impression. This suggests prescribers who relied on subjective
impression have not followed best practice recommendations (Table 10).
Table 10
Correlation between Checking CSPMP by Subjective Impression and Best Practice Behaviors
Check 12month
CSPMP prior
to opioid rx.
Check CSPMP

Correlation Coefficient

by subjective

Sig. (2-tailed)

impression

N

Review
MMEs prior
to opioid rx.

Check
CSPMP every
3 months

Document
concerning
PDMP results

Maintain
opioid dosage
<50 MMEs
per day

Check 12month
CSPMP prior
to opioid rx.

1.000

-.054

.091

.001

-.179

.347

.

.811

.686

.998

.425

.114

22

22

22

22

22

22

Discussion
This DNP project utilized QI through best practice review for prescribing opioids in
patients with chronic non-cancer, non-terminal pain. Best practices included initial PDMP
review prior to prescribing opioid medication for non-cancer, non-terminal pain, reviewing
morphine milligram equivalents (MMEs) of prior prescriptions, <3- month PDMP review for
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patients receiving chronic opioid medication, APRN addressing concerning PDMP review
results, and maintaining an opioid dosage < 50 MMEs. Findings suggest increased APRN
adherence to opioid prescribing best practices after online QI review. The target for the outcome
indicators of 30 percent compliance for all set at baseline and 60 percent at one month post initial
survey/QI activity was met for one indicator, but was not met for four indicators. Findings from
this project supported previous outcomes that self-reported ease of access improved PDMP
utilization initial 12-month PDMP review prior to prescribing opioid medication and <3- month
PDMP review for patients receiving chronic opioid medication. However, results did not
support previous data suggesting practice area was associated with PDMP utilization.
Theoretical framework concepts evaluated in this project included normative beliefs,
attitude, outcome expectancies, barriers and control factors, and behavior intention. Findings
suggest a change in normative beliefs specifically improved adherence to best practice
recommendations as well as an increased percentage of respondents believing peers ought to be
checking the PDMP. This supports theoretical framework concepts of professional and moral
obligation as well. It is possible best practice review signified a new normative behavior,
contributing to improved adherence.
An unexpected finding was the dramatic increase in PDMP registration rates.
Information available from 2017 revealed only 22% prescribers were registered with the
AZCSPMP (Dodge, 2017). The sample in this project reported 100% compliance with the state
mandate for AZCSPMP registration. This is certainly an encouraging finding and suggests the
mandate is aiding APRN compliance with best practice recommendations.
Cost-Benefit Analysis/Budget
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It is estimated that the DNP project director provided 760 donated hours including
preparatory work, survey development, data analysis, documentation, results review, and
presentation. Cost of mailings, follow-up contact, office supplies, and software packages/online
tools were the greatest monetary expense and were an in-kind donation. APRN participation
time completing the pre-/ post-surveys and the QI activity was estimated at 25 minutes. Nonmonetary benefits included improved patient care via best practice behaviors with the goal of
reduced morbidity and mortality. See Appendix H for cost/benefit analysis/budget.
Strengths
A number of strengths and successes were associated with the DNP project. Potential
facilitators for the project included the national opioid crisis and its associated publicity, as well
as Arizona’s well-developed PMDP. This project focused exclusively on APRN practice. It
highlighted APRN practice modification in accordance with best practice recommendations.
Results revealed improvement in AZCSPMP utilization across all best practice behaviors. An
unexpected finding was the markedly increased compliance with the Arizona mandate of PDMP
registration was reported by 100% of respondents. Outcomes supported previous findings that
providers utilize subjective impression as the indicator for CSPMP review and were significantly
correlated with best practice behaviors. Lastly, the data collected contained a number of factors
related to PDMP utilization and barriers and is amenable to further analyses.
Limitations
Despite the noted successes and strengths of the project, there were some limitations,
including those related to project design. Response rate was low, limiting generalizability of
findings. The low response rate was not entirely surprising based upon the original means of
contact by U.S. Postal Service. The goal sample size of 161 was not met, thus the standard
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confidence interval of .80 and a margin of error of 0.05 was not achieved. A repeated measures
design could be utilized in the future to test for significant differences pre- and post-intervention.
Study findings and limitations lay the groundwork for future QI initiatives. Future projects can
build upon this project’s findings and limitations.
Dissemination
The DNP student presented outcomes and recommendations to several stakeholders.
This included the clinical site, the Arizona Board of Nursing, and Dr. John A. Pugliese, the
original survey developer. The DNP student submitted the doctoral Capstone project to
Scholarworks for publication. The DNP student may also pursue additional dissemination
opportunities by presenting at applicable conferences and/or submitting the project summary to
appropriate journals for publication. This best practice review can direct future QI efforts.
Follow-up QI initiatives/projects with APRNs in Arizona as well as other states could be
conducted to assess change over time. Post-project continuation will help ensure sustainability of
change.
Conclusion
Best practices when prescribing opioids for chronic, non-cancer, non-terminal pain is
critical for patient safety and positive outcomes. Opioid overdoses and opioid deaths are
preventable. Targeted interventions are necessary to minimize the morbidity and mortality of
this epidemic. The national publicity of the opioid crisis provides an opportunity to improve
health care. This Capstone project utilized best practices for risk mitigation. Evaluating opioid
prescribing practices and PDMP utilization from a QI perspective opens the door for systematic
change, which can improve the utility of PDMPs and ultimately improve patient safety and
quality of life.
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Appendix C
Invitation to Participate in Project

To my Capstone Project!
I am enrolled in the onIine DNP program at the University of Massachusetts – Amherst.
I am conducting an analysis related to opioid prescribing in Arizona & would be most grateful if you would
be willing to participate.
For more information, please contact me at bvigue@umass.edu or go to www.surveymonkey.com . . .
Best Regards,
Brenda Vigue, APRN, MS, FNP-BC, PMHNP-BC
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Appendix D
Letter Requesting Permission to Use Survey
July 19, 2018
John A. Pugliese, PhD
1616 Capitol Avenue
Suite 74.436, Building 174
Sacramento, CA 95814
Dear Dr Pugliese:
I am a doctoral student enrolled in the Doctorate in Nursing (DNP) program at the University of
Massachusetts Amherst, under the direction of Dr. Terrie Black, DNP Project Chair. Dr. Black can be
reached at tblack@umass.edu. My DNP Capstone Project is entitled, Mitigating Prescription Opioid
Risk: Prescription Drug Monitoring Programs,
I would like your permission to use the Opioid Prescribing by Medical Toxicologists survey in
my doctoral project. I would like to use and print your survey under the following conditions:


I will use the surveys only for my DNP scholarly project and will not sell or use it with any
compensated or curriculum development activities.



I will include the copyright statement on all copies of the instrument.



I will send a copy of my completed DNP scholarly project to your attention upon completion of
the study.
If these are acceptable terms and conditions and/or there are any other considerations you would

like, please contact me by email at bvigue@umass.edu. Thank you.
Sincerely,

Brenda Vigue, APRN, MS, FNP-BC, PMHNP-BC
College of Nursing
University of Massachusetts Amherst
Skinner Hall
651 North Pleasant Street
Amherst, MA 01003-9299
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Appendix F
Preliminary Survey
I.

Do you have prescribing privileges in the state of Arizona? Yes, No—Inclusion question

II.

Do you possess an active DEA certificate for the state of Arizona? Yes, No—Inclusion question

III.

Concerned about misuse of control substances: not concerned at all (0) to a great deal (2).
a.

How concerned are you about prescription drug misuse and abuse among patients in Arizona?

b.

How concerned are you about prescription drug misuse and abuse among patients in the
community where you practice?

IV.

Usefulness of the PDMP: not useful at all (0) to very useful (3).
a.

How useful to you is the Arizona Controlled Substances Prescription Monitoring Program
(CSPMP) for helping manage patients with pain?

b.

How useful to you is the CSPMP for helping build trust with patients?

c.

How useful to you is the CSPMP for informing decisions to prescribe/dispense controlled
substances?

d.

How useful to you is the CSPMP for identifying patients filling prescriptions from multiple
doctors and/or pharmacies?

e.

How useful to you is the CSPMP for identifying patients who misuse or abuse controlled
prescription drugs?

V.

VI.

PDMP normative believes: 11-point scale, 0% to 100%
a.

What percentage of your colleagues do you think uses the CSPMP at least weekly?

b.

What percentage of your colleagues do you feel ought to be using the CSPMP at least weekly?

Professional and moral obligation: Strongly disagree (1) to strongly agree (5)
a.

I have a professional responsibility to check the CSPMP when prescribing/dispensing controlled
substances.

b.

Checking the CSPMP when prescribing/dispensing controlled substances is the right thing to do.

c.

Using the CSPMP when prescribing/dispensing controlled substances is considered standard of
care.

d.

Prescribing/dispensing controlled substances without checking the CSPMP would be morally
wrong.

e.

Checking the CSPMP when prescribing/dispensing controlled substances is not a necessary part of
my job.

VII.

Barriers to use: Strongly disagree (1) to strongly agree (5).
a.

The CSPMP is helpful.

b.

The CSPMP is not relevant to my practice.

c.

The CSPMP is easy to use.

d.

I don’t know how to use the CSPMP.
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Appendix F (continued)
Survey
a.

I have limited or no access to the CSPMP while I practice.

b.

The CSPMP is checked by someone else in the office. Never (0) to always (4).

VIII.

How long have you been using the CSPMP?: Less than three months (1) to more than one year (4).

IX.

How likely are you to use the CSPMP at least once in the next three months? Extremely unlikely (1) to
extremely likely (4).

X.

Gender (M, F)

XI.

Age (7 categories)

XII.

Years in practice (In years)

XIII.

Race/ethnicity
a.

White

b.

Black

c.

American/Alaskan Native

d.

Asian

e.

Native Hawaiian/Pacific Islander

f.

Other

XIV.

Hispanic or Latino (Yes, No)

XV.

Specialty

XVI.

a.

Family practice

b.

Specialty clinic

c.

Women’s health

d.

Behavioral health/psychiatry

e.

Midwifery/OBGYN

f.

Pediatrics

g.

Other

Normative beliefs/best practice (Not from original survey): Less than once/month (1) to every day (6)
a.

I check an initial 12-month PDMP report prior to prescribing opioids for patients with chronic
non-cancer, non-terminal pain.

b.
XVII.

I review the MME of prior prescriptions.

Normative beliefs/best practices—(Not from original survey): Never (1) to always (5)
c.

I check the CSPMP every three months or sooner for patients receiving opiates for chronic noncancer, non-terminal pain.

d.

I document concerning PDMP review results.

e.

I maintain an opioid dosage < 50 morphine milligram equivalents (MMEs) per day.

Note. Reprinted from Pugliese, J. A., Wintemute, G. J., & Henry, G. S. (2018). Psychosocial correlates of clinicians’ prescription drug
monitoring utilization. American Journal of Preventative Medicine, 31, 556. doi: 10.1016/j.amepre.2018.02.009.
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Appendix G
Post-intervention Survey
I.

Concerned about misuse of control substances: not concerned at all (0) to a great deal (2).
a.

How concerned are you about prescription drug misuse and abuse among patients in Arizona?

b.

How concerned are you about prescription drug misuse and abuse among patients in the
community where you practice?

II.

Usefulness of the PDMP: not useful at all (0) to very useful (3).
a.

How useful to you is the Arizona Controlled Substances Prescription Monitoring Program
(CSPMP) for helping manage patients with pain?

b.

How useful to you is the CSPMP for helping build trust with patients?

c.

How useful to you is the CSPMP for informing decisions to prescribe/dispense controlled
substances?

d.

How useful to you is the CSPMP for identifying patients filling prescriptions from multiple
doctors and/or pharmacies?

e.

How useful to you is the CSPMP for identifying patients who misuse or abuse controlled
prescription drugs?

III.

IV.

PDMP normative believes: 11-point scale, 0% to 100%
a.

What percentage of your colleagues do you think uses the CSPMP at least weekly?

b.

What percentage of your colleagues do you feel ought to be using the CSPMP at least weekly?

Professional and moral obligation: Strongly disagree (1) to strongly agree (5)
a.

I have a professional responsibility to check the CSPMP when prescribing/dispensing controlled
substances.

b.

Checking the CSPMP when prescribing/dispensing controlled substances is the right thing to do.

c.

Using the CSPMP when prescribing/dispensing controlled substances is considered standard of
care.

d.

Prescribing/dispensing controlled substances without checking the CSPMP would be morally
wrong.

e.

Checking the CSPMP when prescribing/dispensing controlled substances is not a necessary part of
my job.

V.

Barriers to use: Strongly disagree (1) to strongly agree (5).
a.

The CSPMP is helpful.

b.

The CSPMP is not relevant to my practice.

c.

The CSPMP is easy to use.

d.

I don’t know how to use the CSPMP.

c.

I have limited or no access to the CSPMP while I practice.

d.

The CSPMP is checked by someone else in the office. Never (0) to always (4).
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Appendix G (continued)
Post-intervention Survey
VI.

How long have you been using the CSPMP?: Less than three months (1) to more than one year (4).

VII.

How likely are you to use the CSPMP at least once in the next three months? Extremely unlikely (1) to
extremely likely (4).

VIII.

Subjective impression—(Not from original survey): Never (1) to always (5)
a.

IX.

I check a PDMP report only when I am concerned a patient is misusing their opioid medication.

Normative beliefs/best practice (Not from original survey): Less than once/month (1) to every day (6)
f.

I check an initial 12-month PDMP report prior to prescribing opioids for patients with chronic
non-cancer, non-terminal pain.

g.
X.

I review the MME of prior prescriptions.

Normative beliefs/best practices—(Not from original survey): Never (1) to always (5)
h.

I check the CSPMP every three months or sooner for patients receiving opiates for chronic noncancer, non-terminal pain.

i.

I document concerning PDMP review results.

j.

I maintain an opioid dosage < 50 morphine milligram equivalents (MMEs) per day.

Note. Reprinted from Pugliese, J. A., Wintemute, G. J., & Henry, G. S. (2018). Psychosocial correlates of clinicians’ prescription drug
monitoring utilization. American Journal of Preventative Medicine, 31, 556. doi: 10.1016/j.amepre.2018.02.009.
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Appendix H
Cost/benefit Analysis

Monetary

Survey Monkey access
Office supplies
Toner cartridges
Paper
Misc.
Professional editing
Arizona Board of Nursing
– APRN mailing list
Postcards
Mailing labels
Postage
SPSS statistical software
MONETARY TOTAL
Non-monetary APRNs
Project director – time
Patients

Cost
$224.00

Benefit

$241.95
$67.34
$41.07
$484.00
$100.00
$150.00
$40.00
$595.00
$99.00
$2,042.36
25 minutes Improved pt. care
760 hours Improved pt. care
Reduced morbidity &
mortality

